肝动脉灌注化疗是肝细胞癌的一种可行治疗选择：最新进展
Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update.
作者信息
Hendi Maher, Mou Yiping, Lv Jiemin, Zhang Bin, Cai Xiujun
机构信息
Department of Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Surgery, Zhejiang Provincial Peoples Hospital, Hangzhou, China.
出版信息
Gastrointest Tumors. 2021 Jul 15;8(4):145-152. doi: 10.1159/000516405. eCollection 2021 Oct.
Abstract
BACKGROUND
Hepatic arterial infusion chemotherapy (HAIC) is one option for treating massive tumors and unresectable hepatocellular carcinoma (HCC). However, there is a lack of remedial treatment after these treatments are ineffective or failed.
SUMMARY
Some studies have discovered that HAIC has greater survival in patients with advanced HCC. A previous study has shown that HAIC is effective in the treatment of advanced HCC, and the data on randomized clinical trials are limited and unclear.
KEY MESSAGE
More clinical trials and research are needed in order to make HAIC a standard and recommended therapy for advanced HCC. Our review focuses on the clinical applications of hepatic artery infusion treatment.
摘要
背景
肝动脉灌注化疗（HAIC）是治疗巨大肿瘤和不可切除肝细胞癌（HCC）的一种选择。然而，这些治疗无效或失败后缺乏补救治疗。
总结
一些研究发现，HAIC对晚期HCC患者有更高的生存率。先前的一项研究表明，HAIC在晚期HCC治疗中有效，而随机临床试验的数据有限且不明确。
关键信息
为了使HAIC成为晚期HCC的标准和推荐疗法，需要更多的临床试验和研究。我们的综述重点关注肝动脉灌注治疗的临床应用。
相似文献
1
Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update.肝动脉灌注化疗是肝细胞癌的一种可行治疗选择：最新进展
Gastrointest Tumors. 2021 Jul 15;8(4):145-152. doi: 10.1159/000516405. eCollection 2021 Oct.
2
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.使用改良FOLFOX方案的肝动脉灌注化疗与经动脉化疗栓塞术治疗巨大不可切除肝细胞癌的前瞻性非随机研究。
Chin J Cancer. 2017 Oct 23;36(1):83. doi: 10.1186/s40880-017-0251-2.
3
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.肝动脉灌注化疗与经动脉化疗栓塞术治疗不可切除肝细胞癌的比较：一项系统评价与荟萃分析
Front Bioeng Biotechnol. 2022 Sep 27;10:1010824. doi: 10.3389/fbioe.2022.1010824. eCollection 2022.
4
Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.肝动脉灌注化疗改良 FOLFOX 方案作为经动脉化疗栓塞失败或不适合患者的晚期肝细胞癌的替代治疗选择。
Acad Radiol. 2021 Nov;28 Suppl 1:S157-S166. doi: 10.1016/j.acra.2021.01.024. Epub 2021 Feb 27.
5
Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma.大的不可切除肝细胞癌患者中，氟尿嘧啶、亚叶酸钙和奥沙利铂肝动脉灌注化疗与经动脉化疗栓塞术的成本效益分析
Front Pharmacol. 2022 Apr 26;13:849189. doi: 10.3389/fphar.2022.849189. eCollection 2022.
6
Current Status of Hepatic Arterial Infusion Chemotherapy.肝动脉灌注化疗的现状
Liver Cancer. 2015 Sep;4(3):188-99. doi: 10.1159/000367746. Epub 2015 Aug 12.
7
Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.经肝动脉化疗栓塞术联合肝动脉灌注化疗加 S-1 治疗肝细胞癌。
World J Gastroenterol. 2020 Jul 21;26(27):3975-3988. doi: 10.3748/wjg.v26.i27.3975.
8
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.比较有大血管侵犯和经导管动脉化疗栓塞耐药状态的晚期肝细胞癌患者行肝动脉灌注化疗和索拉非尼治疗的临床结局。
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.
9
Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.肝动脉灌注化疗联合经动脉栓塞治疗不可切除肝细胞癌的疗效与安全性：一项倾向评分匹配队列研究。
JGH Open. 2019 Dec 13;4(3):477-483. doi: 10.1002/jgh3.12285. eCollection 2020 Jun.
10
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.使用阿霉素进行高剂量肝动脉灌注化疗与经动脉化疗栓塞治疗难治性晚期肝细胞癌的对比研究。
Korean J Hepatol. 2010 Dec;16(4):355-61. doi: 10.3350/kjhep.2010.16.4.355.
引用本文的文献
1
AI-Based Quantification of Enhancing Tumor Volume on Contrast-Enhanced MRI to Predict Pathologic Response and Prognosis in HCC After HAIC Plus Targeted Therapy and Immunotherapy.基于人工智能的增强磁共振成像上强化肿瘤体积定量分析，以预测肝动脉灌注化疗联合靶向治疗及免疫治疗后肝癌的病理反应和预后
J Hepatocell Carcinoma. 2025 Jul 21;12:1509-1525. doi: 10.2147/JHC.S527789. eCollection 2025.
2
Clinical features and prognostic factors of patients with inoperable hepatocellular carcinoma treated with chemotherapy: a population-based study.化疗治疗不可切除肝细胞癌患者的临床特征及预后因素：一项基于人群的研究
J Gastrointest Oncol. 2024 Jun 30;15(3):1122-1140. doi: 10.21037/jgo-24-298. Epub 2024 Jun 20.
3
Efficacy and Safety of Hepatic Arterial Infusion Therapy with Cinobufacini in Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Retrospective Cohort Study.华蟾素肝动脉灌注治疗伴大血管侵犯的晚期肝细胞癌的疗效与安全性：一项回顾性队列研究
Cancer Manag Res. 2024 Mar 14;16:163-175. doi: 10.2147/CMAR.S440017. eCollection 2024.
4
Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?肝癌的最佳介入治疗：肝动脉灌注化疗、经动脉化疗栓塞还是碘油载药微球经动脉化疗栓塞？
J Interv Med. 2023 May 2;6(2):59-63. doi: 10.1016/j.jimed.2023.03.001. eCollection 2023 May.
5
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.化疗多样化时代的晚期肝细胞癌肝动脉灌注化疗。
Clin Mol Hepatol. 2023 Jul;29(3):593-604. doi: 10.3350/cmh.2022.0391. Epub 2023 Feb 13.
6
Repeated trans-arterial treatments of LDL-DHA nanoparticles induce multiple pathways of tumor cell death in hepatocellular carcinoma bearing rats.对携带肝癌的大鼠反复进行经动脉注射低密度脂蛋白-二十二碳六烯酸纳米颗粒治疗可诱导肿瘤细胞发生多种死亡途径。
Front Oncol. 2022 Nov 24;12:1052221. doi: 10.3389/fonc.2022.1052221. eCollection 2022.
7
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.肝动脉灌注化疗联合仑伐替尼序贯消融治疗晚期肝细胞癌的疗效和安全性。
Cancer Med. 2023 Mar;12(5):5436-5449. doi: 10.1002/cam4.5366. Epub 2022 Oct 17.
8
Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma.采用FOLFOX方案的经动脉灌注化疗可能是不可切除性肝内胆管癌的一种有效且安全的治疗方法。
J Oncol. 2022 Mar 15;2022:2724476. doi: 10.1155/2022/2724476. eCollection 2022.
本文引用的文献
1
The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017.1990年至2017年全球、区域、国家、年龄和性别层面特定病因所致原发性肝癌的负担及趋势：全球疾病负担研究2017结果
Liver Cancer. 2020 Sep;9(5):563-582. doi: 10.1159/000508568. Epub 2020 Jul 23.
2
International trends in hepatocellular carcinoma incidence, 1978-2012.国际 1978-2012 年肝细胞癌发病率趋势。
Int J Cancer. 2020 Jul 15;147(2):317-330. doi: 10.1002/ijc.32723. Epub 2019 Nov 5.
3
Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.新辅助肝动脉灌注化疗在 A 型 Child-Pugh 分级的晚期肝细胞癌患者中的作用和局限性。
World J Surg Oncol. 2019 Aug 15;17(1):143. doi: 10.1186/s12957-019-1685-6.
4
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).《中国原发性肝癌诊疗规范（2017年版）》
Liver Cancer. 2018 Sep;7(3):235-260. doi: 10.1159/000488035. Epub 2018 Jun 14.
5
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy.晚期肝细胞癌的治疗策略：索拉非尼与肝动脉灌注化疗。
World J Hepatol. 2018 Sep 27;10(9):571-584. doi: 10.4254/wjh.v10.i9.571.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
The hepatocellular carcinoma market.肝细胞癌市场。
Nat Rev Drug Discov. 2019 Jan;18(1):13-14. doi: 10.1038/nrd.2018.146. Epub 2018 Aug 31.
8
Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma.5-氟尿嘧啶持续输注化疗与低剂量顺铂单药治疗晚期肝细胞癌的肝动脉灌注化疗比较
Hepatol Res. 2018 Dec;48(13):1118-1130. doi: 10.1111/hepr.13232. Epub 2018 Aug 23.
9
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.索拉非尼序贯肝动脉灌注化疗治疗晚期肝细胞癌的多中心、开放、非对照Ⅱ期临床研究（HICS55）
BMC Cancer. 2018 Jun 4;18(1):633. doi: 10.1186/s12885-018-4519-y.
10
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.索拉非尼联合低剂量顺铂和氟尿嘧啶肝动脉灌注化疗与索拉非尼单药治疗晚期肝细胞癌的随机、开放标签、3 期试验（SILIUS）
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.
Zotero 插件